Gastroenterology and Hepatology
Gastroenterology is a branch of medicine that deals with normal function and diseases that affect the digestive tract, from mouth to anus and includes hepatology involving the study of the liver, pancreas, gallbladder and biliary tree.
Gastroenterology focuses on the diagnosis and treatment of conditions such gastrointestinal disorders including acute hepatic porphyria, bowel disorders including inflammatory bowel disease, Crohn’s disease, as well as Coeliac disease, hepatitis and pancreatic disorders.
Acute Hepatic Porphyria Learning Zone
Acute Hepatic Porphyria (AHP), a subset of porphyria, refers to a family of rare, genetic diseases characterised by potentially life-threatening attacks and, for some patients, chronic manifestations that negatively impact daily functioning and quality of life (QOL).1 The most common manifestation of attacks is severe, diffuse abdominal pain, although patients can also experience other pain, mood, and gastrointestinal (GI) symptoms.
Featured Learning Zones
Welcome to the Fluid Management Learning Zone. In this Learning Zone we provide an overview of fluid management, including albumin for sepsis and septic shock, guidelines for fluid management in liver cirrhosis and fluid management in cardiac surgery.
Optimising anti-TNF treatment using biosimilars
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Anti-integrins in IBD Learning Zone
The growing understanding of the immunopathogenesis of inflammatory bowel disease (IBD) has provided a variety of novel therapeutic targets. Apart from the tumour necrosis factor-α mediated pathway, which is the target of the first marketed biologics in this indication, several other pathways are involved in triggering an inflammatory response.
Related news and insights
Bristol Myers Squibb announced results from True North, a pivotal Phase III trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients with moderate to severe ulcerative colitis.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for Hepcludex (bulevirtide), from MYR GmbH, intended for the treatment of chronic hepatitis delta virus (HDV) infection in adult patients with compensated liver disease.
Gilead Sciences, Inc. and Galapagos NV announced positive topline results from SELECTION, a randomized, double-blind, placebo-controlled, Phase IIb/III trial evaluating the efficacy and safety of the investigational, oral, once-daily, selective JAK1 inhibitor filgotinib in 1,348 biologic-naïve or biologic-experienced adult patients with moderately to severely active ulcerative colitis (UC).
Early recognition and intervention is essential for survival. The immediate priorities are to control bleeding (surgery and interventional radiology) and maintain vital organ perfusion by transfusing blood and other fluids through...
The guideline has been condensed into two papers,[...] the second describing current therapeutic management [treatment of active disease and maintenance of medically induced remission].